Praxis Precision Medicines, Inc.

Praxis Precision Medicines, Inc. (NASDAQ: PRAX) is a clinical-stage biopharmaceutical company focused on translating genetic insights into therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. The company operates through two proprietary platforms designed to discover and develop precision medicines for neurological conditions.

The Cerebrum platform utilizes small molecule chemistry combined with computational and experimental tools to develop orally available therapies targeting ion channels and other CNS-relevant mechanisms. This platform has generated three clinical-stage product candidates: ulixacaltamide for essential tremor, vormatrigine for focal onset seizures and generalized epilepsy, and relutrigine for developmental and epileptic encephalopathies. The company also in-licensed PRAX-020, a KCNT1 blocker, to UCB Biopharma SRL.

The Solidus platform employs proprietary computational workflows to discover and develop antisense oligonucleotides with optimized drug-like properties. The lead program, elsunersen, targets SCN2A early-onset developmental and epileptic encephalopathy. The platform has also generated three additional novel ASOs in preclinical development targeting PCDH19, SYNGAP1, and SCN2A loss-of-function mutations.

Praxis leverages genetic insights from epilepsy research, where over 900 causal or risk factor genes have been identified, to inform drug discovery across multiple CNS indications. The company employs translational tools including novel transgenic animal models, quantitative electroencephalography biomarkers, and hybrid clinical trial approaches to advance candidates efficiently toward proof-of-concept in patients.

The company's strategy emphasizes collaboration with research institutions, clinical research organizations, patient advocacy groups, and other partners to support internal research and development efforts. Praxis maintains a diversified portfolio with four clinical-stage product candidates across movement disorders and epilepsy, positioning the company to address significant unmet medical needs in rare genetic neurological disorders and more prevalent conditions like essential tremor and common epilepsies. The company website is located at www.praxismedicines.com.